Expertise in
73
conditions

Dr. Mary F. Mulcahy

Oncology
Northwestern Medical Faculty Foundation
675 N Saint Clair St, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
73
conditions
Northwestern Medical Faculty Foundation
675 N Saint Clair St, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mary Mulcahy is an Oncologist in Chicago, Illinois. Dr. Mulcahy is highly rated in 73 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Liver Embolization, and Pancreaticoduodenectomy. Dr. Mulcahy is currently accepting new patients.

Her clinical research consists of co-authoring 125 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Northwestern Medicine Mchenry
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

NORTHWESTERN MEDICAL FACULTY FOUNDATION
675 N Saint Clair St, Chicago, IL 60611
Other Locations
NORTHWESTERN MEDICAL FACULTY FOUNDATION
7 Blanchard Cir, Suite 102, Wheaton, IL 60189
NORTHWESTERN MEDICAL FACULTY FOUNDATION
636 Raymond Dr, Suite 107, Naperville, IL 60563
NORTHWESTERN MEDICAL FACULTY FOUNDATION
1333 W Belmont Ave, Chicago, IL 60657
NORTHWESTERN MEDICAL FACULTY FOUNDATION
250 E Superior St, Chicago, IL 60611

Additional Areas of Focus

Dr. Mulcahy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: August 16, 2024
Intervention Type: Drug, Biological
Study Drugs: Fluorouracil, Irinotecan, Irinotecan hydrochloride, Leucovorin, Leucovorin calcium, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: June 13, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2025
Intervention Type: Drug, Radiation
Study Drug: Adavosertib
Study Phase: Phase 1
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lutetium Lu 177 Dotatate, Triapine
Study Phase: Phase 1
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan
Study Phase: Phase 2
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
Enrollment Status: Terminated
Publish Date: May 20, 2024
Intervention Type: Drug, Other
Study Drug: Tenofovir Alafenamide
Study Phase: Phase 3
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Enrollment Status: Terminated
Publish Date: April 12, 2022
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 25, 2022
Intervention Type: Radiation, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 1
View 9 Less Clinical Trials

125 Total Publications

Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 09, 2025
Similar Doctors
Philip D. Bonomi
Expertise in
22
conditions
Dr. Philip D. Bonomi
Oncology
Expertise in
22
conditions
Dr. Philip D. Bonomi
Oncology
1725 W Harrison St, Suite 855, 
Chicago, IL 
 (2.9 mi)
312-942-5904
Languages Spoken:
English
See accepted insurances

Philip Bonomi is an Oncologist in Chicago, Illinois. Dr. Bonomi is highly rated in 22 conditions, according to our data. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Expertise in
12
conditions
Dr. Jeffrey A. Sosman
Oncology
Expertise in
12
conditions
Dr. Jeffrey A. Sosman
Oncology
675 N Saint Clair St Ste 21-100, 
Chicago, IL 
 (0.4 mi)
312-695-0990
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Sosman is an Oncologist in Chicago, Illinois. Dr. Sosman is highly rated in 12 conditions, according to our data. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Adult Soft Tissue Sarcoma, Chromophobe Renal Cell Carcinoma, and Nephrectomy. Dr. Sosman is currently accepting new patients.

Expertise in
38
conditions
Dr. Marta Batus
Oncology
Expertise in
38
conditions
Dr. Marta Batus
Oncology

Rush University Medical Group

1700 W Van Buren St, 
Chicago, IL 
 (2.8 mi)
312-563-2875
Languages Spoken:
English, Polish, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Marta Batus is an Oncologist in Chicago, Illinois. Dr. Batus is highly rated in 38 conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Adult Soft Tissue Sarcoma, and Small Cell Lung Cancer (SCLC). Dr. Batus is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mulcahy's expertise for a condition
ConditionClose
View All 21 Distinguished Conditions
View All 51 Advanced Conditions
View All 67 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile